Pharmacotherapeutics for dyslipidemia management

被引：2

作者：

El Hussein, Mohamed Toufic ^{[1
,2
]}

Sharma, Aditi ^{[3
]}

Parmar, Komal ^{[4
]}

Shelat, Krupa ^{[5
]}

机构：

[1] Mt Royal Univ, Sch Nursing & Midwifery, Fac Hlth Community & Educ, Calgary, AB, Canada

[2] Rockyview Gen Hosp, Acute Care NP, Med Cardiol Coronary Care Unit, Calgary, AB, Canada

[3] Alberta Childrens Hosp Calgary, Acute Med & surg Pediat Unit, Cardiol Respirol & Gastroenterol, Calgary, AB, Canada

[4] Foothills Med Ctr Calgary, Gen Surg & Surg Oncol, Calgary, AB, Canada

[5] Peter Lougheed Ctr Calgary, Influenza COVID 19 Unit, Calgary, AB, Canada

来源：

NURSE PRACTITIONER | 2023年 / 48卷 / 06期

关键词：

bile acid sequestrants (BAS); fibrates; cholesterol; dyslipidemia; cholesterol absorption inhibitors; ezetimibe; HMG-CoA reductase inhibitors; hyperlipidemia; statins; PCSK9; inhibitors; icosapent ethyl (IPE); CARDIOVASCULAR SOCIETY GUIDELINES; BILE-ACID SEQUESTRANTS; PCSK9; INHIBITORS; DISEASE; PREVENTION; ALIROCUMAB; EFFICACY; THERAPY; EVENTS; SAFETY;

D O I：

10.1097/01.NPR.0000000000000059

中图分类号：

R47 [护理学];

学科分类号：

1011 ;

摘要：

Effective management of dyslipidemia is of paramount importance to prevent cardiovascular (CV) complications. Using current clinical practice guidelines is recommended to correct lipid levels and prevent further pathologic processes. This article presents an overview of treatment options for patients with dyslipidemia and CV disease, with a special focus on the following drug classes: HMG-CoA reductase inhibitors (also called statins), cholesterol absorption inhibitors (ezetimibe), bile acid sequestrants, fibrates, icosapent ethyl, and PCSK9 inhibitors.

引用

页码：36 / 47

页数：12

共 50 条

[1] Management of Dyslipidemia
Gotto, AM
[J]. AMERICAN JOURNAL OF MEDICINE, 2002, 112 : 10s - 18s
[2] PHARMACOTHERAPEUTICS
不详
[J]. UNION MEDICALE DU CANADA, 1987, 116 (03): : 176 - 177
[3] Dyslipidemia management update
Chang, Yingzi
Robidoux, Jacques
[J]. CURRENT OPINION IN PHARMACOLOGY, 2017, 33 : 47 - 55
[4] Management of hypertension and dyslipidemia
Keith C. Ferdinand
Myra A. Kleinpeter
[J]. Current Hypertension Reports, 2006, 8 : 489 - 496
[5] Management of dyslipidemia in children
Sanjay Kalra
Arun Gandhi
Bharti Kalra
Navneet Agrawal
[J]. Diabetology & Metabolic Syndrome, 1
[6] Dietary management of dyslipidemia
Chopra, Arun K.
[J]. INDIAN HEART JOURNAL, 2024, 76 : S65 - S72
[7] Diagnosis and Management of Dyslipidemia
Halawani, Abdalrashid Faisal M.
Alahmari, Zubaidah Saad
Asiri, Dina Abdullah
Albraheem, Abdullah Ahmed
Alsubaie, Abdullah Munahi A.
Alqurashi, Abdulrahman Ghazi
Alturkistani, Feher Mohammed
Albalawi, Mohammed Khamis
Alzaid, Fahad Nasser Abdulrahman
Alsaluli, Mansour Musaad T.
Alghamdi, Mohammad Saleh Sahhab
[J]. ARCHIVES OF PHARMACY PRACTICE, 2019, 10 (04) : 67 - 70
[8] MANAGEMENT OF DYSLIPIDEMIA IN NIDDM
GARG, A
GRUNDY, SM
[J]. DIABETES CARE, 1990, 13 (02) : 153 - 169
[9] Management of hypertension, and dyslipidemia
Ferdinand, Keith C.
Kleinpeter, Myra A.
[J]. CURRENT HYPERTENSION REPORTS, 2006, 8 (06) : 489 - 496
[10] Contemporary Management of Dyslipidemia
Richard A. Ferraro
Thorsten Leucker
Seth S. Martin
Maciej Banach
Steven R. Jones
Peter P. Toth
[J]. Drugs, 2022, 82 : 559 - 576

← 1 2 3 4 5 →